Posted by Michael Wonder on 04 Jun 2025
Chimeric Therapeutics CDH17 receives FDA fast track
4 June 2025 - Chimeric Therapeutics is pleased to announce that the US FDA has granted CHM CDH17 fast track designation.
Chimeric Therapeutics CDH17 was granted fast track designation based on the FDA’s assessment of CHMCDH17’s potential to improve outcomes for patients with gastro-enteropancreatic neuroendocrine tumours who have progressed beyond at least one prior line of therapy in the advanced or metastatic setting.
